Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Key facts

Study ID

NCT04349267

Run by

Bristol-Myers Squibb

People needed

44

Starts

2020-07-14

Expected to finish

2024-08-22

Last updated by the study team

2025-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
• Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
• Eastern cooperative oncology group performance status of 0 or 1
• Women of childbearing potential must agree to follow methods of contraception

You may not qualify if…

• Participants with active, known or suspected autoimmune disease
• Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
• Uncontrolled or significant cardiovascular disease
• History of or with active interstitial lung disease or pulmonary fibrosis
• Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
• History of allergy or hypersensitivity to study drug components
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0028 — Sioux Falls, South Dakota, United States
• Local Institution - 0001 — Germantown, Tennessee, United States
• Local Institution - 0014 — Edmonton, Alberta, Canada
• Local Institution - 0011 — Vancouver, British Columbia, Canada
• Local Institution - 0004 — Toronto, Ontario, Canada
• Local Institution - 0005 — Montreal, Quebec, Canada
• Local Institution - 0013 — Ottawa, Canada
• Local Institution — Mexico City, Mexico City, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.